BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38008278)

  • 1. LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer.
    Gan S; Qu F; Zhang X; Pan X; Xu D; Cui X; Hou J
    Exp Cell Res; 2024 Jan; 434(1):113857. PubMed ID: 38008278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
    Zhang J; Bu X; Wang H; Zhu Y; Geng Y; Nihira NT; Tan Y; Ci Y; Wu F; Dai X; Guo J; Huang YH; Fan C; Ren S; Sun Y; Freeman GJ; Sicinski P; Wei W
    Nature; 2018 Jan; 553(7686):91-95. PubMed ID: 29160310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Prognostic Role for SPOP, DAXX, RARRES1, and LAMP2 as an Autophagy Related Genes in Prostate Cancer.
    Jamali L; Moradi A; Ganji M; Ayati M; Kazeminezhad B; Fazeli Attar Z; Ghaedi H; Ghaderian SMH; Fallah-Karkan M; Ranjbar A
    Urol J; 2020 Mar; 17(2):156-163. PubMed ID: 30882175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
    Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
    Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
    Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
    Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
    Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
    Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
    Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
    Zhang L; Wang X; Li Y; Han J; Gao X; Li S; Wang F
    Clin Transl Med; 2021 Sep; 11(9):e464. PubMed ID: 34586738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
    Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
    EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
    Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
    Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase.
    Kwon JE; La M; Oh KH; Oh YM; Kim GR; Seol JH; Baek SH; Chiba T; Tanaka K; Bang OS; Joe CO; Chung CH
    J Biol Chem; 2006 May; 281(18):12664-72. PubMed ID: 16524876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy.
    Puto LA; Brognard J; Hunter T
    J Biol Chem; 2015 Jun; 290(25):15406-15420. PubMed ID: 25903140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
    Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
    PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
    Gao K; Shi Q; Gu Y; Yang W; He Y; Lv Z; Ding Y; Cao W; Wang C; Wan X
    Cell Death Differ; 2023 Feb; 30(2):475-487. PubMed ID: 36481790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
    Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
    J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
    Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE
    Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
    Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
    Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
    Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
    Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRP11 activates β-catenin to induce PD-L1 expression in prostate cancer.
    Gan S; Ye J; Li J; Hu C; Wang J; Xu D; Pan X; Chu C; Chu J; Zhang J; Zheng J; Zhang X; Xu J; Zhang H; Qu F; Cui X
    J Drug Target; 2020 Jun; 28(5):508-515. PubMed ID: 31865764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
    Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
    Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.